MIRA Pharmaceuticals Announces Positive Toxicology Results for MIRA‑55

What Happened

• On September 1, 2026, MIRA Pharmaceuticals, Inc. announced positive results from completed 7‑day dose‑range finding toxicology and toxicokinetic studies for MIRA‑55, its investigational oral, non‑opioid drug candidate for inflammatory pain. The company said these results will help inform dose selection for the next phase of its ongoing IND‑enabling program and is targeting submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration in the first quarter of 2027, subject to completion of remaining studies and regulatory requirements.

Key Details

• Announcement date: September 1, 2026 (press release filed via 8‑K).
• Studies: Completed 7‑day dose‑range finding toxicology and toxicokinetic studies; results described as positive.
• Drug candidate: MIRA‑55 — oral, non‑opioid, being developed for inflammatory pain.
• Regulatory timeline: Targeting IND submission to FDA in Q1 2027, contingent on successful completion of remaining IND‑enabling studies and applicable regulatory steps.

Why It Matters

• The positive preclinical toxicology and toxicokinetic findings are a material development in MIRA‑55’s IND‑enabling program because they inform dose selection and de‑risk near‑term development steps.
• If MIRA completes remaining studies and files an IND in Q1 2027 as targeted, the program could move into clinical (human) testing, which is a key value‑inflection point for a biotech drug candidate.
• The filing did not include financial results or new guidance; investors should view this as progress on development milestones rather than proof of clinical safety or efficacy in humans.